Opening Up the Findings of Drug Trials

Los Angeles Times by Ricardo Alonso-Zaldivar | Sep. 17, 2007 (Special Report)

Although there is wide agreement that the system for reporting on clinical trials needs an overhaul, there are sharp disagreements on just how to do it. And the issue is in danger of getting short shrift as a Sept. 30 deadline approaches for broader House and Senate legislation to revamp the whole drug safety system.
Clinical trials, in which patients use a new drug and are watched closely for signs of trouble, are considered the gold standard to ... Full Story »

Posted by Dwight Rousu

See All Reviews »

View | |

To:


Separate email addresses with commas.
25 recipients max.

Note:

Review

Member_photo_thumb
4.2
 by Michael Townes Watson - Sep. 20, 2007

This story is very good on informing the reader of the problem that the FDA has in policing new drugs and their adverse effects on consumers. What the story is missing is the back end--the process that the drug manufacturers go through to determine adverse effects, and whether that process is adequate to insure safety and efficacy of the drugs.

(13 answers)

Michael's Rating

Overall
4.2

Good
from 13 answers
Quality
4.2
Facts
4.0
Fairness
4.0
Information
5.0
Sourcing
3.0
Style
4.0
Accuracy
4.0
Balance
3.0
Context
5.0
Popularity
4.0
Recommendation
4.0
Credibility
4.0
More How our ratings work »